nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—ABCB1—peripheral nervous system neoplasm	0.233	1	CbGaD
Fluvoxamine—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0458	0.0843	CbGbCtD
Fluvoxamine—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0394	0.0725	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0366	0.0674	CbGbCtD
Fluvoxamine—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0366	0.0674	CbGbCtD
Fluvoxamine—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0349	0.0642	CbGbCtD
Fluvoxamine—CYP2E1—Dacarbazine—peripheral nervous system neoplasm	0.0304	0.056	CbGbCtD
Fluvoxamine—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0275	0.0506	CbGbCtD
Fluvoxamine—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.022	0.0405	CbGbCtD
Fluvoxamine—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0192	0.0354	CbGbCtD
Fluvoxamine—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0192	0.0354	CbGbCtD
Fluvoxamine—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0184	0.0339	CbGbCtD
Fluvoxamine—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0176	0.0324	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0168	0.031	CbGbCtD
Fluvoxamine—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0168	0.031	CbGbCtD
Fluvoxamine—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.0149	0.0275	CbGbCtD
Fluvoxamine—CYP2E1—Etoposide—peripheral nervous system neoplasm	0.0149	0.0274	CbGbCtD
Fluvoxamine—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0133	0.0245	CbGbCtD
Fluvoxamine—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0126	0.0232	CbGbCtD
Fluvoxamine—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0116	0.0213	CbGbCtD
Fluvoxamine—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0115	0.0212	CbGbCtD
Fluvoxamine—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0107	0.0197	CbGbCtD
Fluvoxamine—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.01	0.0184	CbGbCtD
Fluvoxamine—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00861	0.0158	CbGbCtD
Fluvoxamine—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00821	0.0151	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00789	0.0145	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00766	0.0141	CbGbCtD
Fluvoxamine—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00753	0.0139	CbGbCtD
Fluvoxamine—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00513	0.00945	CbGbCtD
Fluvoxamine—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00492	0.00906	CbGbCtD
Fluvoxamine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00484	0.0089	CbGbCtD
Fluvoxamine—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00451	0.0083	CbGbCtD
Fluvoxamine—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00308	0.00566	CbGbCtD
Fluvoxamine—Asthenia—Vincristine—peripheral nervous system neoplasm	5.77e-05	0.000258	CcSEcCtD
Fluvoxamine—Pneumonia—Epirubicin—peripheral nervous system neoplasm	5.76e-05	0.000258	CcSEcCtD
Fluvoxamine—Drowsiness—Epirubicin—peripheral nervous system neoplasm	5.73e-05	0.000256	CcSEcCtD
Fluvoxamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	5.72e-05	0.000256	CcSEcCtD
Fluvoxamine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	5.72e-05	0.000256	CcSEcCtD
Fluvoxamine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	5.71e-05	0.000256	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	5.68e-05	0.000254	CcSEcCtD
Fluvoxamine—Rash—Dactinomycin—peripheral nervous system neoplasm	5.68e-05	0.000254	CcSEcCtD
Fluvoxamine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	5.66e-05	0.000254	CcSEcCtD
Fluvoxamine—Renal failure—Epirubicin—peripheral nervous system neoplasm	5.63e-05	0.000252	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	5.63e-05	0.000252	CcSEcCtD
Fluvoxamine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	5.62e-05	0.000252	CcSEcCtD
Fluvoxamine—Fatigue—Etoposide—peripheral nervous system neoplasm	5.62e-05	0.000252	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000251	CcSEcCtD
Fluvoxamine—Jaundice—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.00025	CcSEcCtD
Fluvoxamine—Stomatitis—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.00025	CcSEcCtD
Fluvoxamine—Constipation—Etoposide—peripheral nervous system neoplasm	5.57e-05	0.000249	CcSEcCtD
Fluvoxamine—Pain—Etoposide—peripheral nervous system neoplasm	5.57e-05	0.000249	CcSEcCtD
Fluvoxamine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000249	CcSEcCtD
Fluvoxamine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000249	CcSEcCtD
Fluvoxamine—Dysuria—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000249	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	5.52e-05	0.000247	CcSEcCtD
Fluvoxamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	5.52e-05	0.000247	CcSEcCtD
Fluvoxamine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	5.5e-05	0.000246	CcSEcCtD
Fluvoxamine—Sweating—Epirubicin—peripheral nervous system neoplasm	5.49e-05	0.000246	CcSEcCtD
Fluvoxamine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.000246	CcSEcCtD
Fluvoxamine—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000244	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	5.42e-05	0.000243	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000243	CcSEcCtD
Fluvoxamine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.41e-05	0.000242	CcSEcCtD
Fluvoxamine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.4e-05	0.000242	CcSEcCtD
Fluvoxamine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.38e-05	0.000241	CcSEcCtD
Fluvoxamine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	5.37e-05	0.000241	CcSEcCtD
Fluvoxamine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.37e-05	0.00024	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.00024	CcSEcCtD
Fluvoxamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.35e-05	0.000239	CcSEcCtD
Fluvoxamine—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	5.34e-05	0.000239	CcSEcCtD
Fluvoxamine—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	5.33e-05	0.000239	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.33e-05	0.000239	CcSEcCtD
Fluvoxamine—Dizziness—Vincristine—peripheral nervous system neoplasm	5.32e-05	0.000238	CcSEcCtD
Fluvoxamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.31e-05	0.000238	CcSEcCtD
Fluvoxamine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	5.3e-05	0.000237	CcSEcCtD
Fluvoxamine—Rash—Alitretinoin—peripheral nervous system neoplasm	5.26e-05	0.000236	CcSEcCtD
Fluvoxamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.26e-05	0.000235	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	5.25e-05	0.000235	CcSEcCtD
Fluvoxamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.24e-05	0.000235	CcSEcCtD
Fluvoxamine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	5.23e-05	0.000234	CcSEcCtD
Fluvoxamine—Headache—Alitretinoin—peripheral nervous system neoplasm	5.23e-05	0.000234	CcSEcCtD
Fluvoxamine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	5.21e-05	0.000233	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000233	CcSEcCtD
Fluvoxamine—Urticaria—Etoposide—peripheral nervous system neoplasm	5.18e-05	0.000232	CcSEcCtD
Fluvoxamine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000231	CcSEcCtD
Fluvoxamine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000231	CcSEcCtD
Fluvoxamine—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000231	CcSEcCtD
Fluvoxamine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	5.15e-05	0.000231	CcSEcCtD
Fluvoxamine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.15e-05	0.000231	CcSEcCtD
Fluvoxamine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.15e-05	0.000231	CcSEcCtD
Fluvoxamine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000231	CcSEcCtD
Fluvoxamine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000231	CcSEcCtD
Fluvoxamine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.00023	CcSEcCtD
Fluvoxamine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.00023	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000229	CcSEcCtD
Fluvoxamine—Vomiting—Vincristine—peripheral nervous system neoplasm	5.11e-05	0.000229	CcSEcCtD
Fluvoxamine—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.1e-05	0.000228	CcSEcCtD
Fluvoxamine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	5.1e-05	0.000228	CcSEcCtD
Fluvoxamine—Sweating—Doxorubicin—peripheral nervous system neoplasm	5.08e-05	0.000227	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	5.08e-05	0.000227	CcSEcCtD
Fluvoxamine—Rash—Vincristine—peripheral nervous system neoplasm	5.07e-05	0.000227	CcSEcCtD
Fluvoxamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.07e-05	0.000227	CcSEcCtD
Fluvoxamine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	5.06e-05	0.000227	CcSEcCtD
Fluvoxamine—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000226	CcSEcCtD
Fluvoxamine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	5.04e-05	0.000226	CcSEcCtD
Fluvoxamine—Headache—Vincristine—peripheral nervous system neoplasm	5.04e-05	0.000226	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	5.01e-05	0.000224	CcSEcCtD
Fluvoxamine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	5e-05	0.000224	CcSEcCtD
Fluvoxamine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.97e-05	0.000223	CcSEcCtD
Fluvoxamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.96e-05	0.000222	CcSEcCtD
Fluvoxamine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.95e-05	0.000222	CcSEcCtD
Fluvoxamine—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	4.95e-05	0.000221	CcSEcCtD
Fluvoxamine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.87e-05	0.000218	CcSEcCtD
Fluvoxamine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	4.86e-05	0.000218	CcSEcCtD
Fluvoxamine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	4.84e-05	0.000217	CcSEcCtD
Fluvoxamine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	4.8e-05	0.000215	CcSEcCtD
Fluvoxamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.8e-05	0.000215	CcSEcCtD
Fluvoxamine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000215	CcSEcCtD
Fluvoxamine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000214	CcSEcCtD
Fluvoxamine—Nausea—Vincristine—peripheral nervous system neoplasm	4.78e-05	0.000214	CcSEcCtD
Fluvoxamine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	4.77e-05	0.000214	CcSEcCtD
Fluvoxamine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	4.77e-05	0.000214	CcSEcCtD
Fluvoxamine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000213	CcSEcCtD
Fluvoxamine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000213	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	4.73e-05	0.000212	CcSEcCtD
Fluvoxamine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.000211	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	4.7e-05	0.00021	CcSEcCtD
Fluvoxamine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.00021	CcSEcCtD
Fluvoxamine—Asthenia—Etoposide—peripheral nervous system neoplasm	4.68e-05	0.000209	CcSEcCtD
Fluvoxamine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000209	CcSEcCtD
Fluvoxamine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000209	CcSEcCtD
Fluvoxamine—Chills—Epirubicin—peripheral nervous system neoplasm	4.61e-05	0.000207	CcSEcCtD
Fluvoxamine—Pruritus—Etoposide—peripheral nervous system neoplasm	4.61e-05	0.000206	CcSEcCtD
Fluvoxamine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	4.59e-05	0.000206	CcSEcCtD
Fluvoxamine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	4.58e-05	0.000205	CcSEcCtD
Fluvoxamine—Alopecia—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000203	CcSEcCtD
Fluvoxamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.52e-05	0.000202	CcSEcCtD
Fluvoxamine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000202	CcSEcCtD
Fluvoxamine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	4.5e-05	0.000201	CcSEcCtD
Fluvoxamine—Rash—Cisplatin—peripheral nervous system neoplasm	4.48e-05	0.000201	CcSEcCtD
Fluvoxamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.48e-05	0.000201	CcSEcCtD
Fluvoxamine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	4.48e-05	0.0002	CcSEcCtD
Fluvoxamine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.46e-05	0.0002	CcSEcCtD
Fluvoxamine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	4.45e-05	0.000199	CcSEcCtD
Fluvoxamine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000199	CcSEcCtD
Fluvoxamine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	4.41e-05	0.000198	CcSEcCtD
Fluvoxamine—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000197	CcSEcCtD
Fluvoxamine—Tension—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000197	CcSEcCtD
Fluvoxamine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	4.38e-05	0.000196	CcSEcCtD
Fluvoxamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	4.35e-05	0.000195	CcSEcCtD
Fluvoxamine—Back pain—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000194	CcSEcCtD
Fluvoxamine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000193	CcSEcCtD
Fluvoxamine—Dizziness—Etoposide—peripheral nervous system neoplasm	4.31e-05	0.000193	CcSEcCtD
Fluvoxamine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.3e-05	0.000193	CcSEcCtD
Fluvoxamine—Chills—Doxorubicin—peripheral nervous system neoplasm	4.27e-05	0.000191	CcSEcCtD
Fluvoxamine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.00019	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—peripheral nervous system neoplasm	4.22e-05	0.000189	CcSEcCtD
Fluvoxamine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000189	CcSEcCtD
Fluvoxamine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000188	CcSEcCtD
Fluvoxamine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	4.17e-05	0.000187	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.000186	CcSEcCtD
Fluvoxamine—Vomiting—Etoposide—peripheral nervous system neoplasm	4.14e-05	0.000185	CcSEcCtD
Fluvoxamine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	4.14e-05	0.000185	CcSEcCtD
Fluvoxamine—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000185	CcSEcCtD
Fluvoxamine—Agitation—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.000184	CcSEcCtD
Fluvoxamine—Rash—Etoposide—peripheral nervous system neoplasm	4.11e-05	0.000184	CcSEcCtD
Fluvoxamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.1e-05	0.000184	CcSEcCtD
Fluvoxamine—Headache—Etoposide—peripheral nervous system neoplasm	4.08e-05	0.000183	CcSEcCtD
Fluvoxamine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000183	CcSEcCtD
Fluvoxamine—Tension—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000182	CcSEcCtD
Fluvoxamine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000182	CcSEcCtD
Fluvoxamine—Malaise—Epirubicin—peripheral nervous system neoplasm	4.04e-05	0.000181	CcSEcCtD
Fluvoxamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.00018	CcSEcCtD
Fluvoxamine—Vertigo—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.00018	CcSEcCtD
Fluvoxamine—Syncope—Epirubicin—peripheral nervous system neoplasm	4.01e-05	0.00018	CcSEcCtD
Fluvoxamine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	4.01e-05	0.000179	CcSEcCtD
Fluvoxamine—Back pain—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000179	CcSEcCtD
Fluvoxamine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000178	CcSEcCtD
Fluvoxamine—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.96e-05	0.000177	CcSEcCtD
Fluvoxamine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.000176	CcSEcCtD
Fluvoxamine—Cough—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000175	CcSEcCtD
Fluvoxamine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	3.9e-05	0.000175	CcSEcCtD
Fluvoxamine—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000174	CcSEcCtD
Fluvoxamine—Nausea—Etoposide—peripheral nervous system neoplasm	3.87e-05	0.000173	CcSEcCtD
Fluvoxamine—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000173	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000172	CcSEcCtD
Fluvoxamine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.000171	CcSEcCtD
Fluvoxamine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000171	CcSEcCtD
Fluvoxamine—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000171	CcSEcCtD
Fluvoxamine—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000171	CcSEcCtD
Fluvoxamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.00017	CcSEcCtD
Fluvoxamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.8e-05	0.00017	CcSEcCtD
Fluvoxamine—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.76e-05	0.000169	CcSEcCtD
Fluvoxamine—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000167	CcSEcCtD
Fluvoxamine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000167	CcSEcCtD
Fluvoxamine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000167	CcSEcCtD
Fluvoxamine—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.71e-05	0.000166	CcSEcCtD
Fluvoxamine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	3.71e-05	0.000166	CcSEcCtD
Fluvoxamine—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000165	CcSEcCtD
Fluvoxamine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000164	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.65e-05	0.000164	CcSEcCtD
Fluvoxamine—Oedema—Epirubicin—peripheral nervous system neoplasm	3.65e-05	0.000164	CcSEcCtD
Fluvoxamine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000163	CcSEcCtD
Fluvoxamine—Infection—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000162	CcSEcCtD
Fluvoxamine—Cough—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000162	CcSEcCtD
Fluvoxamine—Shock—Epirubicin—peripheral nervous system neoplasm	3.59e-05	0.000161	CcSEcCtD
Fluvoxamine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000161	CcSEcCtD
Fluvoxamine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.00016	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.00016	CcSEcCtD
Fluvoxamine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.00016	CcSEcCtD
Fluvoxamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.00016	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.000158	CcSEcCtD
Fluvoxamine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000158	CcSEcCtD
Fluvoxamine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000158	CcSEcCtD
Fluvoxamine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000158	CcSEcCtD
Fluvoxamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.51e-05	0.000157	CcSEcCtD
Fluvoxamine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.48e-05	0.000156	CcSEcCtD
Fluvoxamine—Anorexia—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000156	CcSEcCtD
Fluvoxamine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000154	CcSEcCtD
Fluvoxamine—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.41e-05	0.000153	CcSEcCtD
Fluvoxamine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000153	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000151	CcSEcCtD
Fluvoxamine—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000151	CcSEcCtD
Fluvoxamine—Infection—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.00015	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.000149	CcSEcCtD
Fluvoxamine—Shock—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000149	CcSEcCtD
Fluvoxamine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000148	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000148	CcSEcCtD
Fluvoxamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000148	CcSEcCtD
Fluvoxamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.3e-05	0.000148	CcSEcCtD
Fluvoxamine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.000147	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000146	CcSEcCtD
Fluvoxamine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.26e-05	0.000146	CcSEcCtD
Fluvoxamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000145	CcSEcCtD
Fluvoxamine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000144	CcSEcCtD
Fluvoxamine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000144	CcSEcCtD
Fluvoxamine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000142	CcSEcCtD
Fluvoxamine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.16e-05	0.000141	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.000141	CcSEcCtD
Fluvoxamine—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.000141	CcSEcCtD
Fluvoxamine—Pain—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.00014	CcSEcCtD
Fluvoxamine—Constipation—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.00014	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	0.000138	CcSEcCtD
Fluvoxamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.06e-05	0.000137	CcSEcCtD
Fluvoxamine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.000136	CcSEcCtD
Fluvoxamine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.01e-05	0.000135	CcSEcCtD
Fluvoxamine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.000135	CcSEcCtD
Fluvoxamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000135	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.99e-05	0.000134	CcSEcCtD
Fluvoxamine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000133	CcSEcCtD
Fluvoxamine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000132	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.92e-05	0.000131	CcSEcCtD
Fluvoxamine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.91e-05	0.00013	CcSEcCtD
Fluvoxamine—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.9e-05	0.00013	CcSEcCtD
Fluvoxamine—Pain—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000129	CcSEcCtD
Fluvoxamine—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000129	CcSEcCtD
Fluvoxamine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.89e-05	0.000129	CcSEcCtD
Fluvoxamine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.89e-05	0.000129	CcSEcCtD
Fluvoxamine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000125	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000124	CcSEcCtD
Fluvoxamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.69e-05	0.00012	CcSEcCtD
Fluvoxamine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.68e-05	0.00012	CcSEcCtD
Fluvoxamine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.67e-05	0.00012	CcSEcCtD
Fluvoxamine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.67e-05	0.00012	CcSEcCtD
Fluvoxamine—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.62e-05	0.000117	CcSEcCtD
Fluvoxamine—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.58e-05	0.000116	CcSEcCtD
Fluvoxamine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.5e-05	0.000112	CcSEcCtD
Fluvoxamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	0.000111	CcSEcCtD
Fluvoxamine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	0.000109	CcSEcCtD
Fluvoxamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.42e-05	0.000108	CcSEcCtD
Fluvoxamine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.39e-05	0.000107	CcSEcCtD
Fluvoxamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.32e-05	0.000104	CcSEcCtD
Fluvoxamine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.31e-05	0.000104	CcSEcCtD
Fluvoxamine—Rash—Epirubicin—peripheral nervous system neoplasm	2.3e-05	0.000103	CcSEcCtD
Fluvoxamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.3e-05	0.000103	CcSEcCtD
Fluvoxamine—Headache—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000102	CcSEcCtD
Fluvoxamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.23e-05	0.0001	CcSEcCtD
Fluvoxamine—Nausea—Epirubicin—peripheral nervous system neoplasm	2.17e-05	9.71e-05	CcSEcCtD
Fluvoxamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	9.62e-05	CcSEcCtD
Fluvoxamine—Rash—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	9.54e-05	CcSEcCtD
Fluvoxamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	9.53e-05	CcSEcCtD
Fluvoxamine—Headache—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	9.48e-05	CcSEcCtD
Fluvoxamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	8.99e-05	CcSEcCtD
